Vcare PharmaTech Completes Full Participant Enrollment in Phase III Clinical Trial of VC005 Topical Gel, Balanced, Highly Selective New-Generation JAK1 Inhibitor, for Atopic Dermatitis
Published Time:
2026-10-20 17:57
Source:
Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) recently announced that its self-developed VC005 topical gel, balanced, highly selective new-generation JAK1 inhibitor for the treatment of mild-to-moderate atopic dermatitis (AD) in adults and adolescents, has successfully completed full participant enrollment in its Phase III clinical trial. This milestone marks steady progress for the topical product toward the NDA.
As a core asset in Vcare PharmaTech’s autoimmune pipeline, VC005 topical gel is administered topically to act directly on lesional skin. It delivers local therapeutic effects with minimal systemic exposure. While optimizing anti-inflammatory efficacy, the gel relieves pruritus more rapidly and maximizes medication safety. It achieves an improved clinical balance between maximal efficacy and favorable tolerability, catering to the needs of long-term, intermittent topical treatment for patients with mild-to-moderate AD. The enrolled Phase III study is a multicenter, randomized, double-blind, placebo-controlled trial. It will further validate the efficacy and safety of VC005 gel in a larger cohort of adult and adolescent subjects with mild-to-moderate AD, generating core evidence for subsequent new drug registration and filing.
About VC005 Topical Gel
VC005 is a balanced, highly selective next-generation JAK1 inhibitor. It exerts potent inhibition of JAK1 combined with moderate inhibition of TYK2 to target the Th2/Th1/Th17 inflammatory axes for improved overall therapeutic efficacy. Currently, both oral and topical formulations in multiple strengths have been developed, forming a product portfolio covering a wide range of indications. The VC005 topical gel adopts a unique pharmaceutical base, it supports high drug loading while maintaining robust stability, favorable safety profile without irritation, and a light, refreshing gel texture to improve patient adherence.In the completed Phase II clinical trial for mild-to-moderate atopic dermatitis, VC005 topical gel demonstrated notable pruritus relief and lesion improvement at the early stage of treatment. Pruritus relief was observed on Day 1, with an approximate 14% reduction in the mean NRSfor pruritus within 12 hours. Around 30% of subjects achieved ≥50% improvement in eczema area and severity index (EASI-50 response) after one week of dosing, translating to meaningful improvements in patients’ quality of life. In terms of safety, the incidence of TRAEswas lower than that of the vehicle group, with no SARsreported and favorable patient tolerability. Pharmacokinetic data showed extremely low plasma exposure, even lower in adolescent populations, with no drug accumulation. VC005 is expected to address the black box warning concerns associated with marketed topical agents of the same target.
About Atopic Dermatitis
Atopic dermatitis (AD) is a chronic, recurrent, inflammatory skin disease characterized by dry skin, intense pruritus, and eczematous rashes, which severely impacts patients' quality of life. Epidemiologically, the global prevalence of AD is approximately 230 million people. In China, the prevalence of AD among adults ranges from 2% to 8%, with over 70 million patients, including 67% with mild cases and 33% with moderate-to-severe cases. According to F&S forecasts, the number of patients will continue to grow at a CAGRof 1.7% from 2025 to 2030. Traditional therapeutic drugs, such as glucocorticoids, are associated with numerous adverse reactions and fail to provide long-term benefits, making it difficult to achieve effective and stable disease control. In contrast, topical small-molecule JAK1-targeted inhibitors are non-glucocorticoid immunosuppressants, which are expected to retain therapeutic efficacy with further improvement in the medication safety for patients with mild-to-moderate symptoms.
Disclaimer
1.This press release shares cutting‑edge R&D progress of the Company for informational purposes only and is not intended for advertising. Information herein is not directed at patients and is for reference by healthcare professionals only.
2.Nothing in this press release constitutes a recommendation for any medicinal product and/or indication.
3.All information contained herein is for reference only. Company press releases and announcements shall in no way substitute for professional medical advice and shall not be construed as medical guidance. Please consult physicians or other qualified healthcare professionals for disease‑specific diagnosis and treatment advice.
4.As of the release date of this document, VC005 Topical Gel have not obtained marketing approval from the NMPA.
5.This press release may contain certain forward‑looking statements. Such statements inherently carry substantial risks and uncertainties. Words including “anticipate”, “believe”, “forecast”, “expect”, “intend” and other similar expressions in connection with the Company constitute forward‑looking statements. The Company assumes no obligation to update such predictive statements on an ongoing basis.
Forward‑looking statements are based on management’s current views, assumptions, expectations, estimates, forecasts and understanding of future events as of the time of issuance. They are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond the Company’s control and difficult to predict. Accordingly, actual outcomes may differ materially from those reflected in forward‑looking statements due to future changes and developments in our business, competitive landscape, political, economic, legal and social conditions.
Neither the Company nor its directors, employees or agents shall bear any liability for (a) any obligation to correct or update forward‑looking statements published on this website; and (b) any liability arising from the non‑realization or inaccuracy of any forward‑looking statements.
Related News
31
2025
/
07
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the completion of full patient enrollment for its Phase II clinical trial of the self-developed, next-generation highly selective JAK1 inhibitor, VC005 topical gel, for the treatment of mild-to-moderate Atopic Dermatitis (AD). This marks a significant milestone in the VC005 gel development program.
03
2025
/
07
Recently, the NDA for Eratrectinib (VC004) capsules, a next-generation anti-resistance TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) has been officially accepted by China's NMPA. Previously granted priority review designation, the drug holds promise as a new treatment option for patients with advanced solid tumors.
30
2025
/
05
Recently, Eratrectinib (VC004) capsules, a self-developed next-generation anti-resistant TRK inhibitor by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), were included in the priority review list by the NMPA, through public notice. This milestone positions the drug within the first tier of next-generation anti-resistant products targeting the same mechanism in China.
21
2025
/
05
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the completion of patient enrollment for its self-developed Class 1 innovative antiplatelet drug, Vicagrel Capsules, in a Phase III clinical trial conducted in China. This study evaluates the efficacy and safety of Vicagrel compared to Clopidogrel in patients with acute coronary syndrome (ACS). The milestone marks a critical step toward Vicagrel’s potential market approval.
09
2025
/
05
On May 8, 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) achieved another major milestone in its self-developed second-generation highly selective JAK1 inhibitor, VC005 tablets. The project, intended for the oral treatment of non-segmental vitiligo received official IND approval from the NMPA (Application No.: CXHL2500200).
28
2025
/
04
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the successful enrollment of the first participant in its Phase II clinical trial for VC005 topical gel, a self-developed next-generation highly selective JAK1 inhibitor, for the treatment of mild-to-moderate atopic dermatitis (AD). The trial aims to evaluate the efficacy of VC005 gel in adult patients with mild-to-moderate AD, providing a critical data for dose selection in future clinical studies and further assesses the drug's safety profile.